caa a22 4500 605478767 CHVBK 20210128100407.0 cr unu---uuuuu 210128e20151101xx s 000 0 eng 10.1007/s10741-015-9502-y doi (NATIONALLICENCE)springer-10.1007/s10741-015-9502-y Chemotherapy-induced cardiomyopathy [Elektronische Daten] [Angela Higgins, Thomas O'Halloran, James Chang] Cardiomyopathy is an adverse outcome of antineoplastic drug therapy that has become increasingly relevant in the management of cancer survivors. As the efficacy of anticancer treatments has improved, long-term outcomes are altered by the development of cardiotoxicity, which may be associated with an even worse prognosis than that of the underlying malignancy. From the research into mechanisms, prevention, and treatment, the specialized field of cardio-oncology has evolved, but the recognition and appropriate management of these patients is important for the general internist and general cardiologist as well. Although antineoplastic chemotherapy can cause multiple forms of cardiotoxicity, including arrhythmia, pericardial disease, valvular dysfunction, and myocardial ischemia, in this review we will focus on chemotherapeutic agents associated with cardiomyopathies, from the anthracyclines to newer, the so-called targeted agents such as tyrosine kinase inhibitors. We also review the diagnostic modalities for chemotherapy-induced cardiomyopathy as well as the prevention and treatment strategies which may prolong the lives of those suffering from cancer. Springer Science+Business Media New York, 2015 Chemotherapy nationallicence Cardiomyopathy nationallicence Heart failure nationallicence Cancer nationallicence Cardio-oncology nationallicence Higgins Angela Department of Medicine, Beth Israel Deaconess Medical Center, Deaconess Building, Suite 306, One Deaconess Road, 02215, Boston, MA, USA aut O'Halloran Thomas Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA aut Chang James Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA aut Heart Failure Reviews Springer US; http://www.springer-ny.com 20/6(2015-11-01), 721-730 1382-4147 20:6<721 2015 20 10741 https://doi.org/10.1007/s10741-015-9502-y text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10741-015-9502-y text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Higgins Angela Department of Medicine, Beth Israel Deaconess Medical Center, Deaconess Building, Suite 306, One Deaconess Road, 02215, Boston, MA, USA aut NATIONALLICENCE 700 1- O'Halloran Thomas Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA aut NATIONALLICENCE 700 1- Chang James Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA aut NATIONALLICENCE 773 0- Heart Failure Reviews Springer US; http://www.springer-ny.com 20/6(2015-11-01), 721-730 1382-4147 20:6<721 2015 20 10741